Glutathione may have implications in the design of 3-bromopyruvate treatment protocols for both fungal and algal infections as well as multiple myeloma

Oncotarget

Volumn 7, Issue 40, 2016, Pages 65614-65626

  Niedzwiecka, Katarzyna ^a   Dylag, Mariusz ^a   Augustyniak, Daria ^a   Majkowska Skrobek, Grazyna ^a   Cal Bakowska, Magdalena ^a   Ko, Young H ^b   Pedersen, Peter L ^c   Goffeau, Andre ^d   Ulaszewski, Stanislaw ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b UM BioPark   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

3 bromopyruvate (3BP); Buthionine sulfoximine; Fungi; Genes expression; Glutathione; MM cells

Indexed keywords

3 BROMOPYRUVATE; ADENOSINE TRIPHOSPHATE; ALKYLATING AGENT; BUTHIONINE SULFOXIMINE; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; BROMOPYRUVATE; ENZYME INHIBITOR; PYRUVIC ACID DERIVATIVE;

ALGAL INFECTION; ARTICLE; CELL DEATH; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; FUNGAL CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; MYCOSIS; NONHUMAN; CELL CULTURE; INFECTION; METABOLISM; METHODOLOGY; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY; PROTOTHECA;

CELLS, CULTURED; ENZYME INHIBITORS; GLUTATHIONE; HUMANS; INFECTION; MULTIPLE MYELOMA; MYCOSES; PROTOTHECA; PYRUVATES; RESEARCH DESIGN;

EID: 84994182406     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11592     Document Type: Article

References (42)

1. Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from the labside to bedside: introduction to a special issue J Bioenerg Biomembr. 2012;44:1-6.
2. Dylag M, Lis P, Ko JH, Pedersen PL, Goffeau A, Ulaszewski S. Use of the composition of 3-bromopyruvate as a second application of a medicament for the treatment of fungal infections. Exclusive right number: patent no. 219802.
3. Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009; 29:4909-18.
4. Shoshan MC. 3-bromopyruvate: Targets and Outcomes. J Bioenerg Biomembr. 2012; 44:7-15.
5. Liu Z, Zhang YY, Zhang QW, Zhao SR, Wu CZ, Cheng X, Jiang CC, Jiang ZW, Liu H. 3-bromopyruvate induces apoptosis in breast cancer cells by down regulating Mcl-1 through the PI3K/Akt signaling pathway. Anticancer Drugs. 2014; 25:447-55.
6. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-14.
7. Casal M, Paiva S, Andrade RP, Gancedo C, Leão C. The lactate-proton symport of Saccharomyces cerevisiae is encoded by JEN1. J Bacteriol. 1999; 181:2620-3.
8. Lis P, Zarzycki M, Ko YH, Casal M, Pedersen PL, Goffeau A, Ulaszewski S. Transport and cytotoxicity of the anticancer drug 3-bromopyruvate in the yeast Saccharomyces cerevisiae. J Bioenerg Biomembr. 2012; 44:155-61.
9. Azevedo-Silva J, Queirós O, Ribeiro A, Baltazar F, Young KH, Peter L Pedersen PL, Preto A, Casal M. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH. Biochem. J. 2015; 467:247-58.
10. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004; 324:269-75.
11. El Sayed SM, El-Magd RM, Shishido Y, Yorita K, Chung SP, Tran DH, Sakai T, Watanabe H, Kagami S, Fukui K. D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. J Bioenerg Biomembr. 2012; 44:513-23.
12. Pocsi I, Prade RA, Penninckx MJ, Glutathione, altruistic metabolite in fungi. Adv Microb Physiol. 2004; 49:1-76.
13. Rojas E, Valverde M, Kala SV, Kala G, Lieberman MW. Accumulation of DNA damage in the organs of mice deficient in gamma-glutamyltranspeptidase. Mutat. Res. 2000; 447:305-16.
14. Feng X, Zhang Y, Wang P, Liu Q, Wang X. Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death. Photochem Photobiol Sci. 2014; 13:1793-803.
15. Dylag M, Lis P, Niedzwiecka K, Ko YH, Pedersen PL, Goffeau A, Ulaszewski S. 3-Bromopyruvate: A novel antifungal agent against the human pathogen Cryptococcus neoformans. Biochem Biophys Res Commun. 2013; 434:322-7.
16. Reliene R, Schiestl RH. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis. 2006; 27:240-4.
17. Meister A. Glutathione metabolism and its selective modification. J Biol Chem. 1988; 263:17205-8.
18. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res. 2003; 13:189-96.
19. Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010; 196:369-405.
20. Rello S, Stockert J, Moreno V, Gamez A, Pacheco M, Juarranz A, Canete M, Villanueva A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis. 2005; 10:201-8.
21. Majkowska-Skrobek G, Augustyniak D, Lis P, Bartkowiak A, Gonchar M, Ko YH, Pedersen PL, Goffeau A, Ulaszewski S. Killing multiple myeloma cells with the small molecule 3-bromopyruvate: implications for therapy. Anticancer Drugs. 2014; 25:673-82.
22. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res. 2000; 256:12-8.
23. Lawen A. Apoptosis-an introduction. Bioessays. 2003; 25:888-96.
24. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr. 2012; 44:163-70.
25. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004; 324:269-75
26. Lis P, Jurkiewicz P, Cal-Bakowska M, Ko YH, Pedersen PL, Goffeau A, Ulaszewski S. Screening the yeast genome for energetic metabolism pathways involved in a phenotypic response to the anti-cancer agent 3-bromopyruvate. Oncotarget. 2016; 7:10153-73. doi: 10.18632/oncotarget.7174.
27. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, Kim SJ, Park JH. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr. 2008; 40: 607-18.
28. Calviño E, Estañ MC, Sánchez-Martín C, Brea R, de Blas E, BoyanoAdánez Mdel C, Rial E, Aller P. Regulation of death induction and chemosensitizing action of 3-bromopyruvate in myeloid leukemia cells: energy depletion, oxidative stress, and protein kinase activity modulation. J Pharmacol Exp Ther. 2014; 348:324-35.
29. Zhang Q, Zhang Y, Zhang P, Chao Z, Xia F, Jiang C, Zhang X, Jiang Z, LiuH. Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells. Genes Cancer. 2014; 5:100-12. doi: 10.18632/genesandcancer.9.
30. Devasagayam TP, Tilak JC, Boloor KK, Sane KS, Ghaskadbi SS, Lele RD. Free radicals and antioxidants in human health: current status and future prospects. J Assoc Physicians India. 2004; 52:794-804.
31. Sadowska-Bartosz I, Bartosz G. The effect of 3-bromopyruvic acid on human erythrocyte antioxidant defense system. Cell Biol Int. 2013; 37: 1285-90.
32. Hellou J, Ross NW, Moon TW. Glutathione, glutathione S-transferase, and glutathione conjugates, complementary markers of oxidative stress in aquatic biota. Environ Sci Pollut Res. 2012; 19:2007-23.
33. Li ZS, Szczypka M, Lu YP, Thiele DJ, Rea PA. The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump. J Biol Chem. 1996; 271:6509-17.
34. Atkinson HJ, Babbitt PC. Glutathione transferases are structural and functional outliers in the thioredoxin fold. Biochemistry. 2009; 48:11108-16.
35. Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci. 1999; 49:156-64.
36. Manna SK, Kuo MT, Aggarwal BB. Overexpression of γ-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1. Oncogene. 1999; 18:4371-82.
37. Sadowska-Bartosz I, Soszynski M, Ulaszewski S, Ko Y, Bartosz G. Transport of 3-bromopyruvate across the human erythrocyte membrane. Cell & Mol Biol Lett. 2014; 19: 201-14.
38. Amberg DC, Burke DJ, Strathern JN. Methods in Yeast Genetics. A Cold Spring Harbor Laboratory Course Manual. Cold Spring Harbor Laboratory Press, 2005, New York, USA.
39. Isenberg HD. Clinical Microbiology Procedures Handbook, 1 ed., Washington, American Society for Microbiology, 1992.
40. Gonzalez B, François J, Renaud M. A rapid and reliable method for metabolite extraction in yeast using boiling buffered ethanol. Yeast. 1997; 13:1347-55.
41. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82:70-7.
42. Schmitt ME, Brown TA, Trumpower BL. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 1990; 18:3091-2.